Stock 543444 FABINO LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Fabino Life Sciences Limited

Equities

543444

INE0DRT01018

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:54 31/05/2024 BST 		5-day change 1st Jan Change
28.73 INR -4.99% Intraday chart for Fabino Life Sciences Limited -4.99% +4.47%
05-28 Fabino Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
2023 Fabino Life Sciences Limited Approves Executive Changes CI

Valuation

Fiscal Period: March 2022 2023
Capitalization 1 57.22 63
Enterprise Value (EV) 1 51.8 64.64
P/E ratio 124 x 600 x
Yield - -
Capitalization / Revenue 1.36 x 1.87 x
EV / Revenue 1.23 x 1.92 x
EV / EBITDA 49.9 x 195 x
EV / FCF -2,682,276 x -9,199,693 x
FCF Yield -0% -0%
Price to Book 1.39 x 1.53 x
Nbr of stocks (in thousands) 2,100 2,100
Reference price 2 27.25 30.00
Announcement Date 30/08/22 18/08/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023
Net sales 1 27.62 75.17 30.59 42.01 33.61
EBITDA 1 3.197 3.194 0.651 1.038 0.3321
EBIT 1 2.945 3.015 0.493 0.7266 0.0154
Operating Margin 10.66% 4.01% 1.61% 1.73% 0.05%
Earnings before Tax (EBT) 1 0.032 0.991 0.427 0.659 0.121
Net income 1 0.001 0.689 0.302 0.4703 0.108
Net margin 0% 0.92% 0.99% 1.12% 0.32%
EPS 2 0.002222 1.531 0.5020 0.2201 0.0500
Free Cash Flow - 15.46 -3.891 -19.31 -7.026
FCF margin - 20.57% -12.72% -45.97% -20.91%
FCF Conversion (EBITDA) - 484.1% - - -
FCF Conversion (Net income) - 2,244.12% - - -
Dividend per Share - - - - -
Announcement Date 26/11/21 26/11/21 26/11/21 30/08/22 18/08/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023
Net Debt 1 24.2 9.14 2.43 - 1.64
Net Cash position 1 - - - 5.42 -
Leverage (Debt/EBITDA) 7.557 x 2.86 x 3.737 x - 4.926 x
Free Cash Flow - 15.5 -3.89 -19.3 -7.03
ROE (net income / shareholders' equity) - 10.8% 3.06% 1.74% 0.26%
ROA (Net income/ Total Assets) - 3.1% 1.06% 1.32% 0.02%
Assets 1 - 22.2 28.62 35.6 542.7
Book Value Per Share 2 13.40 14.90 10.90 19.50 19.60
Cash Flow per Share 2 2.250 3.740 0.5500 2.800 1.150
Capex 1 0.08 - 0.94 0.46 0.07
Capex / Sales 0.28% - 3.07% 1.09% 0.2%
Announcement Date 26/11/21 26/11/21 26/11/21 30/08/22 18/08/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
FABINO LIFE SCIENCES LIMITED Stock Fabino Life Sciences Limited
+4.47% 723K
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 543444 Stock
  4. Financials Fabino Life Sciences Limited